<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04898777</url>
  </required_header>
  <id_info>
    <org_study_id>MD.21.03.437</org_study_id>
    <nct_id>NCT04898777</nct_id>
  </id_info>
  <brief_title>EUS-Guided Choledochoduodenostomy Versus ERCP for Primary Biliary Decompression in Distal Malignant Biliary Obstruction</brief_title>
  <official_title>Endoscopic Ultrasound-Guided Choledochoduodenostomy Versus Endoscopic Retrograde Cholangiopancreatography for Primary Biliary Decompression in Distal Malignant Biliary Obstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant biliary obstruction commonly caused by pancreatic adenocarcinoma,&#xD;
      cholangiocarcinoma and other etiologies like gallbladder carcinoma, hepatocellular carcinoma,&#xD;
      lymphoma, and metastasis to regional solid organs and lymph nodes.&#xD;
&#xD;
      Pancreatobiliary cancers generally present with jaundice, weight loss, and anorexia with&#xD;
      significant impact on quality of life, morbidity, and mortality.&#xD;
&#xD;
      The primary goal of diagnosis and management is curative resection but it's difficult due to&#xD;
      local invasion and distant metastases at the time of clinical presentation. Biliary&#xD;
      decompression helps to reduce symptoms and improve quality of life in patients with malignant&#xD;
      biliary obstruction.&#xD;
&#xD;
      Endoscopically placed stents have become the standard of care for non-surgical biliary&#xD;
      drainage due to their minimal invasiveness compared to percutaneous drainage.&#xD;
&#xD;
      The standard treatment of obstructive jaundice has been ERCP with biliary stent placement&#xD;
      with high success rate in expert hands and low frequency of adverse events.&#xD;
&#xD;
      Endoscopic ultrasound-guided biliary drainage (EUS-BD) has been increasingly used in patients&#xD;
      who underwent failed ERCP. EUS-BD can be performed in several ways, choledochoduodenostomy&#xD;
      (CDS), hepaticogastrostomy (HGS), antegrade (AG) procedure, and rendezvous (RV) technique.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a single center, prospective randomized comparative study that includes 50&#xD;
      patients with distal malignant biliary obstruction including pancreatic head masses, distal&#xD;
      cholangiocarcinoma or papillary carcinoma.&#xD;
&#xD;
      All patients with inclusion criteria will be recruited in the study by simple random sampling&#xD;
      using sealed envelopes until fulfillment of needed sample size for both EUS-BD arm and&#xD;
      ERCP-BD arm.&#xD;
&#xD;
      Study tools:&#xD;
&#xD;
        -  Informed consent will be obtained from each participant sharing in the study.&#xD;
&#xD;
        -  Throughout history taking, complete general examination and local abdominal examination.&#xD;
&#xD;
        -  Laboratory investigations: CBC, Serum creatinine, Liver functions tests (AST, ALT and&#xD;
           Serum Albumin), Alkaline phosphatase, Serum bilirubin and INR.&#xD;
&#xD;
        -  ERCP-BD by papillary approach and EUS-BD by choledochoduodenostomy with transmural stent&#xD;
           placement.&#xD;
&#xD;
        -  All procedures will be performed under deep sedation or general anesthesia in the left&#xD;
           lateral position.&#xD;
&#xD;
        -  Procedural time is recorded.&#xD;
&#xD;
        -  Technical success is considered after stent placement (expanded and patent) with good&#xD;
           bile flow and drainage.&#xD;
&#xD;
        -  Follow up:&#xD;
&#xD;
        -  Lab investigations will be requested at 2 days, 2 and 4 weeks, 3 and 6 months after the&#xD;
           procedure including:&#xD;
&#xD;
      CBC, S.Cr, S.Bil, AST, ALT, S.Alb, ALP and INR.&#xD;
&#xD;
      - Early adverse events (within 48 hours after procedure) including: Pancreatitis,&#xD;
      Cholangitis, Bleeding, Perforation and Peritonitis.&#xD;
&#xD;
        -  Late adverse events include stent dysfunction either due to food impaction, tumor&#xD;
           ingrowth or stent migration.&#xD;
&#xD;
        -  Clinical success is considered at 2 weeks if total bilirubin is less than 50% of&#xD;
           baseline and at 4 weeks if total bilirubin is less than 3mg/dL.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>- Early adverse events (within 48 hours after procedure) including: Pancreatitis, Cholangitis, Bleeding, Perforation and Peritonitis.&#xD;
- Late adverse events include stent dysfunction either due to food impaction, tumor ingrowth or stent migration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of technical success</measure>
    <time_frame>During procedure</time_frame>
    <description>Technical success is considered after successful stent placement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical success</measure>
    <time_frame>4 weeks</time_frame>
    <description>Clinical success is considered at 2 weeks if total bilirubin is less than 50 percent of baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural duration</measure>
    <time_frame>During procedure</time_frame>
    <description>Procedure time was defined as time from biliary cannulation to stent placement in ERCP group, and time from needle puncture of the dilated bile duct to stent placement in EUS-BD group. In cases of difficult cannulation (defined as failed biliary access within 5 min of attempt), we performed early precut fistulotomy for cannulation by experts without involvement of trainees and duodenal intubation time was not included within procedure time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reinterventions</measure>
    <time_frame>6 months</time_frame>
    <description>Re-endoscopy in cases of stent migration, occlusion by food or tumor ingrowth.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Malignant Biliary Obstruction</condition>
  <arm_group>
    <arm_group_label>ERCP-BD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ERCP Biliary Drainage by papillary approach with stent placement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EUS-BD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Endoscopic Ultrasound guided Biliary Drainage by Choledochoduodenostomy with transmural stent placement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Biliary drainage</intervention_name>
    <description>Biliary decompression in cases of distal malignant obstruction by stent placement either using ERCP or EUS.</description>
    <arm_group_label>ERCP-BD</arm_group_label>
    <arm_group_label>EUS-BD</arm_group_label>
    <other_name>Biliary Decompression</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18 years and older.&#xD;
&#xD;
          -  Presence of locally advanced or metastatic pancreatic head mass on CT or magnetic&#xD;
             resonance imaging of the abdomen&#xD;
&#xD;
          -  Absence of duodenal obstruction.&#xD;
&#xD;
          -  Elevated liver tests with serum bilirubin at least 3 times above the upper limit of&#xD;
             normal (1.2 mg/dL).&#xD;
&#xD;
          -  Histologic or cytologic diagnosis of malignancy.&#xD;
&#xD;
          -  Accept sharing in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age younger than 18 years.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Hilar biliary obstruction (as the main lesion or coexisting with distal obstruction).&#xD;
&#xD;
          -  Presence of duodenal obstruction.&#xD;
&#xD;
          -  Histologic or cytologic diagnosis of malignancy.&#xD;
&#xD;
          -  Patients underwent previous intervention for biliary drainage.&#xD;
&#xD;
          -  Previously failed biliary cannulation at ERCP.&#xD;
&#xD;
          -  Prior biliary sphincterotomy or stent placement.&#xD;
&#xD;
          -  Surgically altered anatomy or inability to access the major duodenal papilla.&#xD;
&#xD;
          -  Patients unfit for anesthesia.&#xD;
&#xD;
          -  Patients having uncorrectable coagulopathy or thrombocytopenia.&#xD;
&#xD;
          -  History of allergy to radiocontrast agents.&#xD;
&#xD;
          -  Refuse sharing in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed M Gaheen, MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Y Altonbary, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hazem H Alminshawy, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed G Deiab, A.Professor</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Magdy H Atwa, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed M Gaheen, MSc.</last_name>
    <phone>+201220755170</phone>
    <email>gaheen@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Y Altonbary, MD</last_name>
    <phone>+201005100091</phone>
    <email>Altonbary@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Specialized Medical Hospital</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed M Gaheen, MSc.</last_name>
      <phone>+201220755170</phone>
      <email>gaheen@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ahmed M Gaheen, MSc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Y Altonbary, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hazem H Alminshawy, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed G Deiab, A.Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magdy H Atwa, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ERCP</keyword>
  <keyword>EUS</keyword>
  <keyword>Distal Malignant Biliary Obstruction</keyword>
  <keyword>Choledochoduodenostomy</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

